A detailed history of Met Life Investment Management, LLC transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 34,260 shares of TERN stock, worth $204,189. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,260
Previous 34,260 -0.0%
Holding current value
$204,189
Previous $233,000 22.32%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.54 - $8.2 $50,611 - $91,413
11,148 Added 48.23%
34,260 $233,000
Q1 2024

May 14, 2024

BUY
$4.86 - $8.19 $112,324 - $189,287
23,112 New
23,112 $151,000
Q3 2023

May 09, 2024

BUY
$4.7 - $8.55 $108,626 - $197,607
23,112 New
23,112 $116,000
Q2 2023

Apr 29, 2024

BUY
$7.35 - $13.29 $169,873 - $307,158
23,112 New
23,112 $202,000
Q2 2023

Aug 10, 2023

BUY
$7.35 - $13.29 $169,873 - $307,158
23,112 New
23,112 $202,000

Others Institutions Holding TERN

About Terns Pharmaceuticals, Inc.


  • Ticker TERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,613,800
  • Market Cap $224M
  • Description
  • Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...
More about TERN
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.